Abstract
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Andreas Reiff, Daniel J Lovell, Janet Van Adelsberg, Maria H B Kiss, Steven Goodman, Manuel Ferrandiz Zavaler, Pei-Yun Chen, James A Bolognese, Paul Cavanaugh Jr, Alise S Reicin and Edward H Giannini
The Journal of Rheumatology May 2006, 33 (5) 985-995;
Andreas Reiff
Daniel J Lovell
Janet Van Adelsberg
Maria H B Kiss
Steven Goodman
Manuel Ferrandiz Zavaler
Pei-Yun Chen
James A Bolognese
Paul Cavanaugh Jr
Alise S Reicin
In this issue
The Journal of Rheumatology
Vol. 33, Issue 5
1 May 2006
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Andreas Reiff, Daniel J Lovell, Janet Van Adelsberg, Maria H B Kiss, Steven Goodman, Manuel Ferrandiz Zavaler, Pei-Yun Chen, James A Bolognese, Paul Cavanaugh, Alise S Reicin, Edward H Giannini
The Journal of Rheumatology May 2006, 33 (5) 985-995;
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
Andreas Reiff, Daniel J Lovell, Janet Van Adelsberg, Maria H B Kiss, Steven Goodman, Manuel Ferrandiz Zavaler, Pei-Yun Chen, James A Bolognese, Paul Cavanaugh, Alise S Reicin, Edward H Giannini
The Journal of Rheumatology May 2006, 33 (5) 985-995;